Oxidative stress-induced angiogenesis is mediated by miR-205-5p.
angiogenesis
microRNAs
retinal pigment epithelial cells
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
28
05
2019
revised:
17
10
2019
accepted:
04
11
2019
pubmed:
22
12
2019
medline:
24
4
2021
entrez:
22
12
2019
Statut:
ppublish
Résumé
miR-205-5p is known to be involved in VEGF-related angiogenesis and seems to regulate associated cell signalling pathways, such as cell migration, proliferation and apoptosis. Therefore, several studies have focused on the potential role of miR-205-5p as an anti-angiogenic factor. Vascular proliferation is observed in diabetic retinopathy and the 'wet' form of age-related macular degeneration. Today, the most common treatments against these eye-related diseases are anti-VEGF therapies. In addition, both AMD and DR are typically associated with oxidative stress; hence, the use of antioxidant agents is accepted as a co-adjuvant therapy for these patients. According to previous data, ARPE-19 cells release pro-angiogenic factors when exposed to oxidative insult, leading to angiogenesis. Matching these data, results reported here, indicate that miR-205-5p is modulated by oxidative stress and regulates VEGFA-angiogenesis. Hence, miR-205-5p is proposed as a candidate against eye-related proliferative diseases.
Identifiants
pubmed: 31863632
doi: 10.1111/jcmm.14822
pmc: PMC6991635
doi:
Substances chimiques
MIRN205 microRNA, human
0
MicroRNAs
0
RNA, Messenger
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1428-1436Informations de copyright
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Références
J Cell Mol Med. 2020 Jan;24(2):1428-1436
pubmed: 31863632
J Cell Physiol. 2009 Jun;219(3):544-52
pubmed: 19142872
Cell Mol Biol (Noisy-le-grand). 2018 Mar 31;64(4):1-5
pubmed: 29631677
J Cell Mol Med. 2016 Aug;20(8):1457-66
pubmed: 26999719
Expert Opin Ther Targets. 2017 Oct;21(10):959-966
pubmed: 28831824
PLoS One. 2015 Dec 03;10(12):e0143969
pubmed: 26633009
Angiogenesis. 2017 Feb;20(1):175-181
pubmed: 27695972
Int Ophthalmol. 2019 Sep;39(9):2023-2031
pubmed: 30386955
Exp Biol Med (Maywood). 2017 Feb;242(3):275-285
pubmed: 27651436
Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34
pubmed: 11033038
Blood. 2014 Jan 30;123(5):625-31
pubmed: 24300855
Biosci Rep. 2017 Mar 15;37(2):
pubmed: 28122882
Oncologist. 2019 Apr;24(4):521-528
pubmed: 30266892
Mol Vis. 2006 Oct 17;12:1175-84
pubmed: 17102797
Am J Ophthalmol. 2013 Jan;155(1):1-35.e13
pubmed: 23245386
PLoS One. 2016 Dec 9;11(12):e0167684
pubmed: 27936052
Front Pharmacol. 2018 Nov 05;9:1280
pubmed: 30455645
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8287-92
pubmed: 21536891
Prog Retin Eye Res. 2008 Jul;27(4):331-71
pubmed: 18653375
Oncol Lett. 2018 Aug;16(2):1715-1721
pubmed: 30008858
Molecules. 2018 Dec 13;23(12):
pubmed: 30551603
J Cell Mol Med. 2013 Nov;17(11):1475-83
pubmed: 24118735
Microvasc Res. 2019 Jul;124:43-50
pubmed: 30853343
Biol Chem. 2014 Feb;395(2):203-30
pubmed: 24127541
Dev Ophthalmol. 2016;55:28-37
pubmed: 26502333
Int J Mol Sci. 2017 Sep 14;18(9):
pubmed: 28906427
J Cell Biochem. 2017 Dec;118(12):4854-4861
pubmed: 28543858
Am J Transl Res. 2018 Feb 15;10(2):563-572
pubmed: 29511451
Mol Biol Rep. 2016 Oct;43(10):1079-87
pubmed: 27411920
J Cell Mol Med. 2018 Nov;22(11):5244-5256
pubmed: 30133118
Adv Exp Med Biol. 2016;854:79-85
pubmed: 26427397
Oncol Res. 2019 Apr 08;:
pubmed: 30982496
Toxicol Rep. 2014 Mar 27;1:12-30
pubmed: 28962222
Cancer Biomark. 2019;25(1):101-113
pubmed: 30909190
Prog Retin Eye Res. 2003 Jan;22(1):1-29
pubmed: 12597922
Am J Transl Res. 2017 Sep 15;9(9):4300-4307
pubmed: 28979703
Cell Physiol Biochem. 2017;41(4):1413-1423
pubmed: 28315863
Cell Cycle. 2019 Feb;18(4):413-424
pubmed: 30739530
Free Radic Biol Med. 2010 Dec 1;49(11):1603-16
pubmed: 20840865
N Engl J Med. 2011 May 19;364(20):1897-908
pubmed: 21526923
Pharmazie. 2019 Mar 1;74(3):154-156
pubmed: 30961681
PLoS One. 2012;7(7):e41462
pubmed: 22859986
Mol Aspects Med. 2012 Aug;33(4):399-417
pubmed: 22510306
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9
pubmed: 23264323
Vet Pathol. 2014 Jul;51(4):759-74
pubmed: 24045890
Mol Vis. 2006 Dec 22;12:1649-59
pubmed: 17200665
J Ocul Pharmacol Ther. 2018 May;34(4):346-353
pubmed: 29389239
Oncol Lett. 2018 Aug;16(2):2207-2214
pubmed: 30008920
Redox Biol. 2016 Apr;7:78-87
pubmed: 26654980
Cutan Ocul Toxicol. 2018 Jun;37(2):121-126
pubmed: 28707489
Curr Eye Res. 2017 Dec;42(12):1659-1666
pubmed: 28937872
Curr Pharm Des. 2018;24(40):4726-4741
pubmed: 30644339
Oncol Rep. 2012 Apr;27(4):1200-6
pubmed: 22159356
Biochim Biophys Acta. 2013 Aug;1830(8):4117-29
pubmed: 23618697
AIMS Mol Sci. 2016;3(2):196-221
pubmed: 27239555
J Clin Exp Ophthalmol. 2016 Jun;7(3):
pubmed: 27917303